Cervical artery dissections (CAD) are a common cause of ischemic cerebrovascular events among the younger and middle-aged population. Altogether, CAD counts for up to 15% of all causes of stroke in patients aged 50 or younger. Among the known etiological causes, especially addressing the younger population with mechanical traumas and whiplash injuries are regarded as the main culprits. However, cases of spontaneous dissection are also widespread, with risk factors such as hypertension, migraine, and lifestyle factors increasing the risk of occurrence. Clinically, the symptoms associated with a cerebrovascular event caused by CADs are highly variable and can be classified as either compressive symptoms (such as Horner’s syndrome and cervical pain) or stroke syndromes attributable to cerebral ischemia. Therefore, establishing an early diagnosis might be particularly challenging as it requires particular attention and quick clinical reasoning when interviewing the patient. With these certain particularities, our main focus was to conduct a prospective study involving up to 54 patients who were diagnosed with CAD in our clinical facility between January 2015 and December 2022, with the focus of assessing certain individual parameters attributable to each patient and their influence and prognosis value for their short and long term evolution. An important emphasis was placed on parameters such as topographical localization, clinical presentation, severity of the questioned cerebrovascular event, outcomes, and causative factors. Statistical validity tools were applied when possible.

Epilepsy is one of the most common chronic neurological disorders worldwide, affecting millions of individuals and imposing a substantial cognitive, psychological, social, and economic burden. Despite significant advances in epilepsy research, key questions remain unresolved regarding the mechanisms underlying drug resistance, cognitive impairment, depression, and sudden unexpected death in epilepsy, as well as the contribution of recurrent seizures in promoting neuronal and glial injury. Addressing these challenges requires reliable biomarkers capable of accurately reflecting disease activity and detecting ongoing brain damage. In this review, we summarize the current evidence on biofluid biomarkers of neuronal and glial damage in epilepsy and seizures and discuss their potential clinical relevance. Particular attention is given to biomarkers associated with major pathways involved in epileptogenesis, including neuroinflammation, oxidative stress, neurodegeneration, blood–brain barrier disruption, altered gene expression, and synaptic remodeling. Emerging evidence suggests that circulating and cerebrospinal fluid biomarkers may provide valuable insights into seizure-related brain injury and the molecular mechanisms underlying epilepsy. Although none of these markers has yet been adopted in routine clinical practice, they represent promising tools for improving diagnosis, prognostic assessment, patient stratification, and the development of more personalized therapeutic strategies.